Drugs / Δ9-tetrahydrocannabinol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05121506 | Nov 2021 → Jan 2022 | — | Gefion Canada Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Δ9-tetrahydrocannabinol | “Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are two naturally occurring phytocannabinoids found in cannabis.” NCT05121506 ↗ |
| Known as | THC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05121506 ↗ |
| Action | Activate | “THC is a potential partial agonist of the CB1 receptor, and it produces its effects through direct binding.” NCT05121506 ↗ |
| Route | Topical | “A single topical dose of CBD and THC will be administered with GT4 technology.” NCT05121506 ↗ |